BOSTON--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the ...

Gilead Sciences Says Viread Meets Goal in Hepatitis B Trial FOSTER CITY, Calif. -- Gilead Sciences, Inc. today announced that Study 102, a Phase III clinical trial evaluating the company's once-daily ...

Pharmacokinetic data from the GS-US-174-0144 trial has been added to the labeling The labeling for Viread (tenofovir disoproxil fumarate; Gilead Sciences) has been updated to include use in chronic ...

Gilead Sciences Inc.'s Viread gained FDA approval in adult patients with chronic hepatitis B virus, bolstering the company's HBV arsenal, which already includes the widely prescribed Hepsera. The ...

LONDON (Reuters) - U.S. biotechnology company Gilead Sciences Inc said on Thursday a European committee had recommended approving its Viread drug as a treatment for hepatitis B. Viread is already ...

Gilead Sciences, Inc.Patrick O’Brien, +1 650-522-1936 (Investors)Stephen Head, +44 (208) 587-2359 (Media, Europe)Cara Miller, +1 650-522-1616 (Media, U.S.) Gilead Sciences, Inc. (Nasdaq: GILD) today ...

Aug. 13 -- TUESDAY, Aug. 12 (HealthDay News) -- Viread (tenofovir disoproxil fumarate) has been approved by the U.S. Food and Drug Administration to treat chronic hepatitis B infection in adults. The ...

Please provide your email address to receive an email when new articles are posted on . Long-term tenofovir treatment in pediatric patients with chronic hepatitis B was well tolerated and correlated ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Tenofovir reduced the severity of ...

About one-third of patients with chronic hepatitis B maintained a profile consistent with inactive disease 1 year after withdrawal from treatment in the randomized HBRN trial, which compared tenofovir ...

LOS ANGELES, June 6 (Reuters) - Gilead Sciences Inc. said on Wednesday that a late-stage clinical trial showed its HIV drug Viread met its main goal of reducing viral levels and liver inflammation in ...